{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 53,
  "pageCount": 55,
  "prevPage": 52,
  "nextPage": 54,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a grid layout to categorize clinical trials by disease stage and patient population, highlighting established standards of care (SoC) with hatched patterns.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/53",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-53",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Leading the future of lung cancer treatment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e3612e9-a8b7-4112-9695-9679ee13ed40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.75,
        "y": 0.38
      },
      "kind": "list",
      "text": "Establishing Tagrisso as backbone TKI in EGFRm; Imfinzi leading IO in unresectable; Advancing best-in-class ADCs; Delivering next-wave bispecifics; Developing novel combinations; Investing in new technologies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f674238-07d9-497c-9e76-b7be42c14f16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.04,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Compugen (rilvegostomig).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0754ac4-6323-47a1-99d8-76654b1beda7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.65,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "table",
      "text": "Matrix of clinical trials by stage (resectable, unresectable, metastatic) and tumor driver (IO sensitive, EGFRm, Other, HER2m)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b25d73fb-aa82-454e-a200-35682c9892ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bc9815d-1e2c-400e-a846-04a697a5baba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "AstraZeneca in lung cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0311404-9cb7-4b58-beaf-2adce6d61516",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "44ef3500-a396-4d7c-ae82-53a4eb45beb2",
      "evidence": "table/data: Matrix of clinical trials by stage (resectable, unresectable, metastatic) and tumor driver (IO sensitive, EGFRm, Other, HER2m)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "72857964-e325-4521-9740-3af69a8502dc",
      "evidence": "The slide organizes clinical trials into a grid based on disease stage and tumor driver type.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}